| Purity: | 99 |
|---|---|
| Model Number: | 53179-13-8 |
| Brand Name: | NJBNSTEROID |
| Grade Standard: | Medicine Grade |
| Type: | Anti-fibrotic |
| Place of Origin: | China (Mainland) |
| EINECS No.: | 53179-13-8 |
| MF: | C12H11NO |
| Other Names: | Pirfenidone |
| CAS No.: | 53179-13-8 |
| Sample: | Free |
| Market: | Worldwide |
Quick Details
Specifications
Pirfenidone 53179-13-8 Broad-spectrum Anti-fibrotic Effect
_______________________________________________________________________________________
Pirfenidone
|
Name |
Pirfenidone |
|
CAS |
53179-13-8 |
|
MF |
C12H11NO |
|
MW |
185.22 |
|
Purity |
99%min |
|
Appearance |
Off-White Solid |
|
Usage |
Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver |
|
Synonyms |
5-methyl-1-phenyl-2(1h)-pyridon; amr-69; PIRFENIDONE; 5-METHYL-1-PHENYL-1H-PYRIDIN-2-ONE; 5-METHYL-1-PHENYL-2(1H)-PYRIDINONE; 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE; 5-Methyl-N-phenyl-2-1H-pyridone; Pirfenidone also see 5-Methyl-1-Phenyl-2(1H)-Pyridinone |
|
Categories |
Aromatics Compounds; Aromatics; Heterocycles; Intermediates & Fine Chemicals; Pharmaceuticals; Cytokine signaling; Inhibitors |
_______________________________________________________________________________________
Description of Pirfenidone
Pirfenidone (PFD) is a novel kind of pyridine ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It entered into market in Shionogi, Japan in 2008 and has been approved by the US food and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has demonstrates its effectiveness in treating idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treating some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis. Furthermore, it is also widely applied in the phase II clinical study in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibromatosis, youth I type of neurofibromatosis and plexiform neurofibromas, diabetes together with kidney disease.
_______________________________________________________________________________________
COA
|
Product |
Pirfenidone |
Batch No. |
150301 |
|
Man. Date |
Mar. 30,2015 |
Expiry date |
Mar. 29,2018 |
|
Testing date |
Mar. 30,2015 |
Report date |
Mar. 31,2015 |
|
Quantity |
30kg |
Quality standard |
Enterprise Standard |
|
Items |
Specifications |
Results |
|
|
Appearance |
A little yellow to white powder |
Pass |
|
|
Identification |
IR As stipulation |
Pass |
|
|
Loss on drying |
No more than 1.0% |
0.22% |
|
|
Heavy metal |
No more than 20ppm |
Pass |
|
|
Sulphated ash |
No more than 0.2% |
0.10% |
|
|
Any impurity |
No more than 0.5% |
0.13% |
|
|
Total impurity |
No more than 1.0% |
0.30% |
|
|
Assay |
99.0%~101.0% |
99.70% |
|
|
Conclusion |
Qualified |
||
_______________________________________________________________________________________
Application of Pirfenidone
1. Idiopathic pulmonary fibrosis degeneration
2. Liver Fibrosis
3. Renal fibrosis disease
4. Multiple Sclerosis
5. Myocardial fibrosis
6. Neoplastic diseases: neurofibroma, leiomyoma, and malignant gliomas.
7. Prevention of fibrosis after the organ transplant.
8. Rheumatoid arthritis.